| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2024 | $8.50 | Buy | Ascendiant Capital Markets |
8-K - Envoy Medical, Inc. (0001840877) (Filer)
SCHEDULE 13D/A - Envoy Medical, Inc. (0001840877) (Subject)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
424B4 - Envoy Medical, Inc. (0001840877) (Filer)
424B4 - Envoy Medical, Inc. (0001840877) (Filer)
EFFECT - Envoy Medical, Inc. (0001840877) (Filer)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
SCHEDULE 13G - Envoy Medical, Inc. (0001840877) (Subject)
S-1MEF - Envoy Medical, Inc. (0001840877) (Filer)
S-1/A - Envoy Medical, Inc. (0001840877) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50
Fastest customizable press release news feed in the world
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) through the alternatives permitted under Listing Rule 5550(b).As previously disclosed, the Company received a notice from Nasdaq on February 25, 2025, indicating that it was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (MVLS) of $35
White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry."We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical. "As the industry realizes the wisdom and flexibility of our appro
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen Taylor Closing of $30 million in gross proceeds in upsized offering, with up to an additional $48 Million upon exercise of milestone warrants, provides potential funding through commercialization Company hosting Fireside Chat with Dr. Theodore McRackan, on February 25th at 10 a.m. ET, to discuss his initial experiences as clinical trial's leading implanterWhite Bear Lake, Minnesota--(Newsfile Corp. - February 19, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutio
45 of 56 Patients Implanted; Enrollment Completion Anticipated by End of MarchWhite Bear Lake, Minnesota--(Newsfile Corp. - February 17, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced continued progress in enrollment for its pivotal clinical trial of the investigational fully implanted Acclaim® cochlear implant.To date, 45 patients have been successfully implanted and are officially enrolled in the study. The trial calls for a total of 56 implanted participants. In other words, Envoy Medical has completed over 80% of targeted enrollment. The Company expects this pivotal clini
$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashOffering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and managementNet proceeds extend anticipated cash runway into second half of 2027, beyond expected PMA submission; if milestone-linked warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond first full year of commercializationWhite Bear Lake, Minnesota--(Newsfile Cor
$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cashWhite Bear Lake, Minnesota--(Newsfile Corp. - February 11, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the pricing of an upsized public offering of an aggregate of 75,000,000 shares of its Class A common stock (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 45,000,000 shares of Class A common stock (or pre-funded warrants in lieu thereof) and Series A-2 common w
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held February 5th are now available for on-demand viewing. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through February 10th. Please Schedule 1x1 Meetings here Febru
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Small Cap Growth Virtual Investor Conference to be held February 5th. Individual investors, institutional investors, advisors, and analysts are invited to attend.REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. Please Schedule 1x1 Meetings Here "We are proud to highlight this diverse roster of companies that demonstrate the innovation taking pl
WHITE BEAR LAKE, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that management will participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026. Small Cap Growth Virtual Investor Conference Presentation Details:Date: Thursday, February 5, 2026Time: 10:00 A.M. ETREGISTER HERE A question-and-answer session will follow the presentation, during which investors may submit questions in real time. If attendees are not able to join the live event, a link to the recording will be available on Envoy's Investor Relations webs
Enrollment momentum accelerates as Company advances toward full enrollmentWhite Bear Lake, Minnesota--(Newsfile Corp. - December 18, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that its pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant has achieved yet another milestone by reaching the midway point of the study's full enrollment target.Despite holiday scheduling and year-end operating room constraints, enrollment is progressing at a steady pace. Sites report actively screening numerous potential candidates. Full enrollment is currentl
Live Leadership Updates
This live feed shows all institutional transactions in real time.
Live finance-specific insights
Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser
WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently
Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A
Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to
WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the second quarter ended June 30, 2024. "We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochle
The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its "breakthrough" fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate Highlights from Q1 2024 All three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester, MN) have completed their 12-m
Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones Recent bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, seeks to open a pathway to insurance coverage for the Company's Esteem® Fully Implanted Active Middle Ear Implant WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023. Financial and
Interim Findings from Early Feasibility Trial Provide Important Learnings and Feedback Ahead of Pivotal Clinical Trial Planned for 2024 Virtual Fireside Chat to be held December 7 WHITE BEAR LAKE, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. ("Envoy Medical") (NASDAQ:COCH), a hearing health company, today is providing a business update and its financial results for the quarter ended September 30, 2023. The Company will host a virtual fireside chat event on December 7, which will cover a range of topics, including introductions to the technology, financial and clinical aspects of the business, as well as potential participation from cochlear implant key opinion leader